eoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer

Erasmus MC0 sites300 target enrollmentTBD

Conditions<p>Oesophageal cancer, oesofaguscarcinoom, esophageal cancer, active surveillance</p>10017998

Overview

Phase: N/A
Intervention: Not specified
Conditions: <p>Oesophageal cancer, oesofaguscarcinoom, esophageal cancer, active surveillance</p>
Sponsor: Erasmus MC
Enrollment: 300
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Erasmus MC

Eligibility Criteria

Inclusion Criteria

•\- Patients who are planned to undergo neoadjuvant chemoradiotherapy according to CROSS, followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophago\-gastric junction, without distant dissemination;
•\- Age \=18;

Exclusion Criteria

•\- Language difficulty, dementia or altered mental status prohibiting the understanding and giving of informed consent and to complete quality of life questionnaires;
•\- Non\-FDG\-avid tumour at baseline PET\-CT scan.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

Phase 3

eoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancercarcinoma of the oesophagusoesophageal cancer1001799010017991

NL-OMON50242Erasmus MC, Universitair Medisch Centrum Rotterdam738

Recruiting

Phase 3

Cancer injection before surgery vs after surgery in stomach cancerHealth Condition 1: C16- Malignant neoplasm of stomach

CTRI/2021/01/030183Jawaharlal Institute of Postgraduate Medical Education and Reserach

Active, Not Recruiting

Phase 1

Chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastasesThe CHARISMA randomized multicenter clinical trial

EUCTR2013-004952-39-NLErasmus MC Cancer Institute224

Completed

Phase 3

eo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases ;The CHARISMA randomized multicenter clinical trialLiver metastases colorectal cancer1001981510017998

NL-OMON44796Erasmus MC, Universitair Medisch Centrum Rotterdam224

Not Yet Recruiting

N/A

Chemotherapy followed by versus surgery alone in high-risk patients with colorectal liver metastasesColorectal liver metastases, clinical risk score, high risk patients, colorectale levermetastasen, klinische risico score, hoog risico patienten

NL-OMON27498Prof. Dr. C. VerhoefErasmus MC Cancer Institute224